Trial Profile
Phase 1 dose-escalation, safety / tolerability and preliminary efficacy study of intratumoral and subcutaneous administration of GEN0101 in patients with recurrence of castration resistant prostate cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs GEN 0101 (Primary) ; GEN 0101 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Ishihara Sangyo Kaisha
- 01 May 2020 Results published in the Cancer Science
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 18 Oct 2017 Status changed from recruiting to completed.